scholarly journals P6‐51: Primary pulmonary multi‐drug resistant tuberculosis on silicotic lung

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 248-248
2019 ◽  
Author(s):  
Yitagesu Habtu ◽  
Tesema Bereku ◽  
Girma Alemu ◽  
Ermias Abera

BACKGROUND Ethiopia is one of among thirty high burden countries of multi-drug resistant tuberculosis (MDR-TB) in the regions of world health organization. Contextual evidence on the emergence of the disease is limited at a program level. OBJECTIVE The aim of the study is to explore patient-provider factors that may facilitate the emergence of multi-drug resistant tuberculosis. METHODS We used a phenomenological study design of qualitative approach from June to July, 2015. We conducted ten in-depth interviews and 4 focus group discussions with purposely selected patients and providers. We designed and used an interview guide to collect data. Verbatim transcribes were exported to open code 3.4 for emerging thematic analysis. Domain summaries were used to support core interpretation. RESULTS The study explored patient-provider factors facilitating the emergence of multi-drug resistant tuberculosis. These factors as underlying, health system and patient-related factors. Especially, the a shows conflicting finding between having a history of discontinuing drug-susceptible tuberculosis and emergence of multi-drug resistant tuberculosis. CONCLUSIONS The patient-provider factors may result in poor early case identification, adherence to and treatment success in drug sensitive or multi-drug resistant tuberculosis. Our study implies the need for awareness creation about multi-drug resistant tuberculosis for patients and further familiarization for providers. This study also shows that patients developed multi-drug resistant tuberculosis though they had never discontinued their drug-susceptible tuberculosis treatment. Therefore, further studies may require for this discording finding.


2016 ◽  
Vol 9 (8) ◽  
pp. 1025-1037 ◽  
Author(s):  
T. V. A. Nguyen ◽  
T. B. T. Cao ◽  
O. W. Akkerman ◽  
S. Tiberi ◽  
D. H. Vu ◽  
...  

2021 ◽  
Vol 120 (3) ◽  
pp. 284a
Author(s):  
Joaquim T. Marquês ◽  
Catarina Faria ◽  
Susana Santos ◽  
Maria da Soledade Santos ◽  
Filomena Martins ◽  
...  

Epidemics ◽  
2021 ◽  
pp. 100471
Author(s):  
Jūlija Pečerska ◽  
Denise Kühnert ◽  
Conor J. Meehan ◽  
Mireia Coscollá ◽  
Bouke C. de Jong ◽  
...  

2013 ◽  
Vol 46 (5) ◽  
pp. 600-620 ◽  
Author(s):  
K. L. HOLLOWAY ◽  
K. STAUB ◽  
F. RÜHLI ◽  
M. HENNEBERG

SummaryThis study investigated the trends in tuberculosis mortality through time in Switzerland. Information on the decline in mortality before chemotherapies were introduced may be useful in developing countries where drug-resistant tuberculosis is now becoming a major problem. Swiss data were collected from historical records and comparative data were obtained from the literature for England and Wales, New York, Japan, Brazil and Sierra Leone. Logistic curves were fitted to examine the rate of decline before introduction of pharmacotherapies and these show that the decline would have continued without the introduction of chemical therapies, including antibiotics. In Switzerland, England and Wales and New York, the decline had occurred long before the introduction of specific anti-tuberculosis agents. In Brazil and Japan, chemical therapy was co-incident with the decline in tuberculosis mortality rates. Overall, it is suggested that the effective control of tuberculosis can be achieved through a combination of chemical interventions, conservative therapy (rest, good nutrition, ventilation, etc.) as well as public health interventions addressing hygiene, nutrition, reducing exposure to infections and educating the population about tuberculosis.


Sign in / Sign up

Export Citation Format

Share Document